Precision medicine in diabetes: Is it time?

Diabetes Care

Volumn 39, Issue 7, 2016, Pages 1085-1088

  Florez, Jose C ^a,b,c  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METFORMIN;

BINDING SITE; BODY MASS; CLINICAL DECISION MAKING; CLINICAL TRIAL (TOPIC); CONFERENCE PAPER; DIAGNOSTIC ACCURACY; DRUG EFFICACY; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC VARIABILITY; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; LIFESTYLE MODIFICATION; NEXT GENERATION SEQUENCING; NON INSULIN DEPENDENT DIABETES MELLITUS; PERSONALIZED MEDICINE; PREDICTIVE VALUE; PREVALENCE; SENSITIVITY AND SPECIFICITY; SINGLE NUCLEOTIDE VARIANT;

EID: 84975883920     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc16-0586     Document Type: Conference Paper

References (27)

1. Tuomi T, Carlsson A, Li H, et al. Clinical and genetic characteristics of type 2 diabetes with and without GAD antibodies. Diabetes 1999;48: 150-157
2. Banerji MA, Chaiken RL, Huey H, et al. GAD antibody negative NIDDM in adult black subjects with diabetic ketoacidosis and increased frequency of human leukocyte antigen DR3 and DR4. Flatbush diabetes. Diabetes 1994;43: 741-745
3. Haaland WC, Scaduto DI, Maldonado MR, et al. A-beta-subtype of ketosis-prone diabetes is not predominantly a monogenic diabetic syndrome. Diabetes Care 2009;32:873-877
4. Gale EA. Latent autoimmune diabetes in adults: a guide for the perplexed. Diabetologia 2005;48:2195-2199
5. Rolandsson O, Palmer JP. Latent autoimmune diabetes in adults (LADA) is dead: long live autoimmune diabetes! Diabetologia 2010; 53:1250-1253
6. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015; 38:140-149
7. Collins FS. Exceptional opportunities in medical science: a view from the National Institutes of Health. JAMA 2015;313:131-132
8. McCarty CA, Chisholm RL, Chute CG, et al.; eMERGE Team. The eMERGE Network: a consortium of biorepositories linked to electronic medical records data for conducting genomic studies. BMC Med Genomics 2011;4:13
9. McCarthy MI. Genomic medicine at the heart of diabetes management. Diabetologia 2015; 58:1725-1729
10. Pociot F, Akolkar B, Concannon P, et al. Genetics of type 1 diabetes: what's next? Diabetes 2010;59:1561-1571
11. Billings LK, Florez JC. The genetics of type 2 diabetes: what have we learned from GWAS? Ann N Y Acad Sci 2010;1212:59-77
12. McCarthy MI. Genomics, type 2 diabetes, and obesity. N Engl J Med 2010;363:2339-2350
13. Dimas AS, Lagou V, Barker A, et al.; MAGIC Investigators. Impact of type 2 diabetes susceptibility variants on quantitative glycemic traits reveals mechanistic heterogeneity. Diabetes 2014;63:2158-2171
14. Yaghootkar H, Scott RA, White CC, et al. Genetic evidence for a normal-weight "metaboli-cally obese" phenotype linking insulin resistance, hypertension, coronary artery disease, and type 2 diabetes. Diabetes 2014;63:4369-4377
15. Walford GA, Porneala BC, Dauriz M, et al. Metabolite traits and genetic risk provide complementary information for the prediction of future type 2 diabetes. Diabetes Care 2014;37: 2508-2514
16. de Miguel-Yanes JM, Shrader P, Pencina MJ, et al.; MAGIC Investigators; DIAGRAM+ Investigators. Genetic risk reclassification for type 2 diabetes by age below or above 50 years using 40 type 2 diabetes risk single nucleotide polymorphisms. Diabetes Care 2011;34:121-125
17. Oram RA, Patel K, Hill A, et al. A type 1 diabetes genetic risk score can aid discrimination between type 1 and type 2 diabetes in young adults. Diabetes Care 2016;39:337-344
18. Hivert MF, Jablonski KA, Perreault L, et al.; DIAGRAM Consortium; Diabetes Prevention Program Research Group. Updated genetic score based on 34 confirmed type 2 diabetes Loci is associated with diabetes incidence and regression tonormoglycemiainthe diabetesprevention program. Diabetes 2011;60:1340-1348
19. Hivert MF, Christophi CA, Franks PW, et al.; Diabetes Prevention Program Research Group. Lifestyle and metformin ameliorate insulin sensitivity independently of the genetic burden of established insulin resistance variants in Diabetes Prevention Program participants. Diabetes 2016;65:520-526
20. Pearson ER, Starkey BJ, Powell RJ, Gribble FM, Clark PM, Hattersley AT. Genetic cause of hyperglycaemia and response to treatment in diabetes. Lancet 2003;362:1275-1281
21. Pearson ER, Flechtner I, Njølstad PR, et al.; Neonatal Diabetes International Collaborative Group. Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. N Engl J Med 2006; 355:467-477
22. Babenko AP, Polak M, Cavé H, et al. Activating mutations in the ABCC8 gene in neonatal diabetes mellitus. N Engl J Med 2006;355:456-466
23. Kahn SE, Haffner SM, Heise MA, et al.; ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355:2427-2443
24. Zhou K, Bellenguez C, Spencer CC, et al.; GoDARTS and UKPDS Diabetes Pharmacoge-netics Study Group; Wellcome Trust Case Control Consortium 2; MAGIC Investigators. Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes. Nat Genet 2011;43:117-120
25. Jablonski KA, McAteer JB, de Bakker PI, et al.; Diabetes Prevention Program Research Group. Common variants in 40 genes assessed for diabetes incidence and response to metfor-min and lifestyle intervention in the Diabetes Prevention Program. Diabetes 2010;59:2672-2681
26. Li L, Cheng WY, Glicksberg BS, et al. Identification of type 2 diabetes subgroups through topological analysis of patient similarity. Sci Transl Med 2015;7:311ra174
27. Zeevi D, Korem T, Zmora N, et al. Personalized nutrition by prediction of glycemic responses. Cell 2015;163:1079-1094